AOA (Diagnostic Equipment) key facts
as of Oct 2026- Developer of an early disease detection platform designed to revolutionize early-stage cancer detection for women.
- AOA (Diagnostic Equipment) is valued at approximately $65.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $56.5M across 1 recorded rounds; the latest was Seed Round ($2.5M) in May 2021.
- Notable investors include Creative Destruction Lab, MassChallenge, Pioneer Fund, Mana Ventures, Impact Assets — 54 tracked in total.
- Status: Privately Held (backing).
Valued at $65.0M at its later-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 54 names
- ·Watch AOA (Diagnostic Equipment): the Monday email on marks, rounds and moves
AOA (Diagnostic Equipment) funding rounds
1 roundsWho backs AOA (Diagnostic Equipment)
54+AOA (Diagnostic Equipment) valuation
AOA (Diagnostic Equipment) was valued at $65 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has AOA (Diagnostic Equipment) raised?
AOA (Diagnostic Equipment) has raised $56.5 million in total; 1 of its rounds is on record. The largest on record was a $2.5 million seed round in May 2021.
AOA (Diagnostic Equipment) investors
54 investors are on record for AOA (Diagnostic Equipment), including Creative Destruction Lab, MassChallenge, Pioneer Fund and Mana Ventures. By type, the record holds 12 venture capital firms and 3 angel investors. The seed round in May 2021 drew 17 investors.
Comparable companies
Comparable diagnostic equipment names by valuation on PrivateMarketView: SiPhox Health ($185 million), NanoMosaic ($85 million) and Oral Genome ($19.9 million).
About AOA (Diagnostic Equipment)
Developer of an early disease detection platform designed to revolutionize early-stage cancer detection for women. The company offers a multi-omics approach powered by glycolipids, tumor marker gangliosides, lipids, and proteins, enabling healthcare providers to set a new gold standard in early cancer diagnostics and improve life-saving outcomes.
- Industry
- Diagnostic Equipment
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2020
- Employees
- 23
- Website
- aoadx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.